New combo therapy shows promise for Hard-to-Treat cancers
NCT ID NCT06220318
First seen Dec 26, 2025 · Last updated May 21, 2026 · Updated 15 times
Summary
This study tests a new drug (C019199) combined with an immunotherapy (sintilimab) in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 155 adults with various advanced cancers will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, China
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Conditions
Explore the condition pages connected to this study.